Cue Biopharma, Inc. Current Assets
Cue Biopharma, Inc. (CUE) had Current Assets of $26.62 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-14
- 2026-06-30: Assets, Current $26.62M.
- 2026-03-31: Assets, Current $26.39M.
- 2025-12-31: Assets, Current $36.98M.
- 2025-09-30: Assets, Current $25.82M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $26.62M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $26.39M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $36.98M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $25.82M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $30.84M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $15.93M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $25.14M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $37.26M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $33.90M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $44.67M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $51.45M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $57.52M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $60.94M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $68.75M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $77.19M 10-K · filed 2024-03-28 | $77.19M 10-K · filed 2023-03-21 |
| 2022-09-30 | $61.70M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $69.00M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $75.95M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $68.47M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $70.25M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $79.68M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $77.41M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $87.53M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $93.56M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $88.35M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $51.19M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $61.02M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $32.99M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $29.87M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $31.97M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $40.61M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $40.61M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $49.25M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $55.93M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $65.07M 10-K · filed 2019-03-14 | $65.06M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |